• Oral Protein Delivery
  • Cell Receptor Targeting
  • Immune System Masking
  • Low Cost of Goods
  • cGMP Manufacturing

SDG's technology is focused on the use of bi-layer phopholipid carriers that range in size from 20-50 nanometers. The Company's systems can be manufactured according to current Good Manufacturing Practices (cGMP) at commercial quantities, and SDG focuses on delivering systems that fit into pharmaceutical and consumer product cost of goods parameters. Shelf life stability for SDG's bio-nano carriers is rigorously tested and can be demonstrated in many product iterations to be in excess of two years at accelerated temperature and humidity. These carriers are designed to be compatible with the following components:

  • Cell receptor targeting molecules, including but not limited to essentially all monoclonal antibodies, hepatocyte targeting molecules, skin binding molecules, and mucin binding molecules
  • Active payloads, including large proteins such as insulin and interferon, small molecules, diagnostic imaging agents, nutraceutical ingredients, and consumer product actives, including fragrances, conditioners, sunscreens and hair care actives
  • Immune masking agents that are 100 times smaller than polyethylene glycol (PEG), the standard masking agent in the pharma industry

SDG has evidence from multiple human clinical studies in patients with Type 1 diabetes, Type 2 diabetes, and hepatitis C virus that its delivery systems enable the oral delivery of proteins such as insulin and interferon. In conjunction with its partners and on its own, the Company is actively pursuing the development of oral protein delivery applications to treat major diseases.